Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.
Metastatic breast cancer
Platinum-based chemotherapy
Visceral crisis
Journal
Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
20
10
2020
revised:
04
03
2021
accepted:
14
03
2021
pubmed:
3
4
2021
medline:
7
10
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
Although the prognosis of metastatic breast cancer (BC) has improved, some patients still develop high burden metastases or visceral crisis (VC) and polychemotherapy is commonly used in these cases. Data reporting the real effectiveness of this strategy are scanty. Therefore, the outcomes of patients with metastatic BC treated with platinum-based chemotherapy (P-ChT) at the Jules Bordet Institute during the period of January 2008 and December 2018 were retrospectively reviewed. The presence of VC was defined according to ABC 4 criteria. 441 patients were identified: visceral metastases were observed in 430 (97.5%) while 261 (59.2%) presented VC. As for metastatic BC subtype, 255 (57.8%) had ER-positive/HER2-negative, 41 (9.3%) ER-positive/HER2-positive, 34 (7.7%) ER-negative/HER2-positive and 111 (25.1%) triple-negative BC. Median number of prior treatment lines was 3.8 (0-12). Median OS with P-ChT in the entire cohort was 6.13 months. Patients with VC had lower OS than patients without VC (8.6 vs 3.7 months; p < 0.001). On multivariate analysis, the variables correlated with worse OS were hyperbilirubinemia (HR 1.90; 95% CI 1.34-2.75), ECOG ≥2 (HR 1.77; 95% CI 1.13-2.78) and ECOG ≥3 (HR 2.52; 95% CI 1.48-4.28), and >3 previous treatment lines (HR 2.27; 95% CI 1.53-3.21). Of the 261 patients with VC, 106 (40.5%) presented a resolution of the VC which correlated with better OS (9.3 vs 2.0 months, HR 0.27; 95% CI 0.21-0.36). Patients who overcome VC benefit from P-ChT with OS similar to patients without VC. In this analysis, hyperbilirubinemia, poor ECOG and >3 previous treatment lines were significant prognostic factors in the overall study population.
Sections du résumé
BACKGROUND/METHODS
METHODS
Although the prognosis of metastatic breast cancer (BC) has improved, some patients still develop high burden metastases or visceral crisis (VC) and polychemotherapy is commonly used in these cases. Data reporting the real effectiveness of this strategy are scanty. Therefore, the outcomes of patients with metastatic BC treated with platinum-based chemotherapy (P-ChT) at the Jules Bordet Institute during the period of January 2008 and December 2018 were retrospectively reviewed. The presence of VC was defined according to ABC 4 criteria.
RESULTS
RESULTS
441 patients were identified: visceral metastases were observed in 430 (97.5%) while 261 (59.2%) presented VC. As for metastatic BC subtype, 255 (57.8%) had ER-positive/HER2-negative, 41 (9.3%) ER-positive/HER2-positive, 34 (7.7%) ER-negative/HER2-positive and 111 (25.1%) triple-negative BC. Median number of prior treatment lines was 3.8 (0-12). Median OS with P-ChT in the entire cohort was 6.13 months. Patients with VC had lower OS than patients without VC (8.6 vs 3.7 months; p < 0.001). On multivariate analysis, the variables correlated with worse OS were hyperbilirubinemia (HR 1.90; 95% CI 1.34-2.75), ECOG ≥2 (HR 1.77; 95% CI 1.13-2.78) and ECOG ≥3 (HR 2.52; 95% CI 1.48-4.28), and >3 previous treatment lines (HR 2.27; 95% CI 1.53-3.21). Of the 261 patients with VC, 106 (40.5%) presented a resolution of the VC which correlated with better OS (9.3 vs 2.0 months, HR 0.27; 95% CI 0.21-0.36).
CONCLUSION
CONCLUSIONS
Patients who overcome VC benefit from P-ChT with OS similar to patients without VC. In this analysis, hyperbilirubinemia, poor ECOG and >3 previous treatment lines were significant prognostic factors in the overall study population.
Identifiants
pubmed: 33799232
pii: S0960-9776(21)00341-6
doi: 10.1016/j.breast.2021.03.002
pmc: PMC8044724
pii:
doi:
Substances chimiques
Platinum
49DFR088MY
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-94Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest MAF: none. RSC, SF: Travel grant from Pfizer for the ESMO conference 2019. DE: Funding for his fellowship (2018–2019: Novartis. Speaker fee: Janssen. AA: Advisory role, speaker fees and research funding for his institute from: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma. EA: honoraria and advisory board: Roche/GNE, Novartis, Seattle Genetics and Zodiacs; travel grants: Roche/GNE, GSK/Novartis; co-principal investigator of the LORELEI trial (NCT02273973). Research grant for his institute: Roche/GNE, Astra-Zeneca, Novartis, and Servier.
Références
Am J Clin Oncol. 2005 Apr;28(2):195-200
pubmed: 15803016
Pharmacol Res. 2018 Jun;132:47-68
pubmed: 29604436
Invest New Drugs. 2008 Aug;26(4):363-8
pubmed: 18165864
Ann Oncol. 2014 Dec;25(12):2357-2362
pubmed: 25231953
World J Oncol. 2017 Aug;8(4):105-109
pubmed: 29147444
Psychooncology. 2017 Jun;26(6):770-778
pubmed: 27437905
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
J Clin Oncol. 2016 Sep 1;34(25):3069-103
pubmed: 27217461
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
NPJ Breast Cancer. 2019 Jan 17;5:5
pubmed: 30675515
Cancer Chemother Pharmacol. 2006 May;57(5):640-6
pubmed: 16163537
Ann Oncol. 2000 Sep;11(9):1155-60
pubmed: 11061611
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
JAMA Oncol. 2020 Jan 01;6(1):116-124
pubmed: 31563959
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Ann Oncol. 2018 Mar 1;29(3):669-680
pubmed: 29342248
Patient Educ Couns. 2016 Jul;99(7):1146-1155
pubmed: 26873544
Clin Cancer Res. 2013 Oct 1;19(19):5456-64
pubmed: 23938289
Breast Cancer Res. 2018 Oct 19;20(1):123
pubmed: 30340505
Lancet Oncol. 2020 Mar;21(3):345-357
pubmed: 32035020
Ann Oncol. 2008 Nov;19(11):1847-52
pubmed: 18567607
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
BMC Palliat Care. 2018 Feb 17;17(1):29
pubmed: 29454337
Cancer. 2014 Jun 1;120(11):1743-9
pubmed: 24967463
BMC Cancer. 2018 Aug 20;18(1):839
pubmed: 30126360
Lancet. 2014 May 17;383(9930):1721-30
pubmed: 24559581
Clin Transl Oncol. 2017 May;19(5):616-624
pubmed: 27853985
J Clin Oncol. 2018 Sep 10;36(26):2736-2740
pubmed: 29939838
Cochrane Database Syst Rev. 2017 Jun 23;6:CD003374
pubmed: 28643430
Int J Qual Health Care. 2016 Sep;28(4):456-69
pubmed: 27353273
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
J Clin Transl Hepatol. 2014 Jun;2(2):95-102
pubmed: 26357620
Mol Oncol. 2011 Feb;5(1):5-23
pubmed: 21147047
Ann Oncol. 2011 Apr;22(4):848-856
pubmed: 20924076
BMJ. 2011 Aug 25;343:d4920
pubmed: 21868477
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Lancet Oncol. 2009 Jun;10(6):615-21
pubmed: 19482250
JAMA. 2009 Aug 19;302(7):741-9
pubmed: 19690306